Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study

BACKGROUND: Dual pathway inhibition with 2.5 mg rivaroxaban twice daily plus 100 mg aspirin once daily may be a promising alternative to 100 mg aspirin antiplatelet therapy for the prevention of cardiovascular events in patients with coronary artery disease and/or peripheral arterial disease. Howeve...

Descripción completa

Detalles Bibliográficos
Autores principales: Petersohn, Svenja, Pouwels, Xavier, Ramaekers, Bram, ten Cate-Hoek, Arina, Joore, Manuela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Cardiovascular Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457457/
https://www.ncbi.nlm.nih.gov/pubmed/32223323
http://dx.doi.org/10.1177/2047487320913380

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457457/
https://www.ncbi.nlm.nih.gov/pubmed/32223323
http://dx.doi.org/10.1177/2047487320913380

Ejemplares similares